INOVIO PHARMACEUTICALS INC's ticker is INO and the CUSIP is 45773H201. A total of 187 filers reported holding INOVIO PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 1.11 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $139,768 | -18.2% | 359,300 | -6.1% | 0.00% | – |
| Q2 2023 | $170,920 | -85.7% | 382,800 | -73.7% | 0.00% | – |
| Q1 2023 | $1,195,324 | -35.8% | 1,457,713 | +22.1% | 0.00% | – |
| Q4 2022 | $1,862,396 | -52.5% | 1,193,843 | -47.5% | 0.00% | – |
| Q3 2022 | $3,923,000 | +54.6% | 2,273,709 | +55.0% | 0.00% | – |
| Q2 2022 | $2,538,000 | +16.9% | 1,466,888 | +142.6% | 0.00% | – |
| Q1 2022 | $2,171,000 | -79.1% | 604,765 | -71.0% | 0.00% | -100.0% |
| Q4 2021 | $10,406,000 | -33.7% | 2,085,487 | -4.9% | 0.00% | -33.3% |
| Q3 2021 | $15,704,000 | -22.5% | 2,193,262 | +0.4% | 0.00% | -25.0% |
| Q2 2021 | $20,257,000 | -14.6% | 2,185,185 | -14.5% | 0.00% | -20.0% |
| Q1 2021 | $23,709,000 | +23.3% | 2,554,874 | +17.6% | 0.01% | 0.0% |
| Q4 2020 | $19,225,000 | -45.2% | 2,172,256 | -28.2% | 0.01% | -44.4% |
| Q3 2020 | $35,101,000 | -41.1% | 3,026,060 | +36.7% | 0.01% | -57.1% |
| Q2 2020 | $59,643,000 | +561.2% | 2,213,100 | +82.5% | 0.02% | +425.0% |
| Q1 2020 | $9,021,000 | +5538.1% | 1,212,600 | +2405.4% | 0.00% | – |
| Q4 2019 | $160,000 | +6.0% | 48,400 | -6.1% | 0.00% | – |
| Q2 2019 | $151,000 | -41.9% | 51,556 | -26.2% | 0.00% | – |
| Q1 2019 | $260,000 | -43.0% | 69,849 | -38.8% | 0.00% | – |
| Q4 2018 | $456,000 | -50.3% | 114,046 | -30.9% | 0.00% | – |
| Q3 2018 | $917,000 | -55.7% | 165,032 | -68.8% | 0.00% | -100.0% |
| Q2 2018 | $2,072,000 | -10.8% | 528,519 | +7.1% | 0.00% | 0.0% |
| Q1 2018 | $2,324,000 | -24.6% | 493,510 | -33.8% | 0.00% | -50.0% |
| Q4 2017 | $3,082,000 | -22.3% | 746,019 | +19.3% | 0.00% | -33.3% |
| Q3 2017 | $3,965,000 | +2009.0% | 625,534 | +2517.3% | 0.00% | – |
| Q2 2017 | $188,000 | -57.8% | 23,900 | -64.5% | 0.00% | – |
| Q1 2017 | $446,000 | -27.9% | 67,308 | -24.6% | 0.00% | – |
| Q4 2016 | $619,000 | +72.9% | 89,254 | +132.4% | 0.00% | – |
| Q3 2016 | $358,000 | +7060.0% | 38,400 | +5522.3% | 0.00% | – |
| Q4 2015 | $5,000 | -99.8% | 683 | -99.8% | 0.00% | -100.0% |
| Q3 2015 | $2,438,000 | +2579.1% | 421,813 | +3673.9% | 0.00% | – |
| Q2 2015 | $91,000 | -31.1% | 11,177 | -22.1% | 0.00% | – |
| Q4 2014 | $132,000 | +30.7% | 14,340 | +52.8% | 0.00% | – |
| Q2 2014 | $101,000 | – | 9,385 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON ASSOCIATES LP | 784,679 | $643,437 | 0.10% |
| Green Alpha Advisors, LLC | 146,300 | $119,966 | 0.08% |
| Virtus ETF Advisers LLC | 54,106 | $44,367 | 0.02% |
| Cedar Brook Financial Partners, LLC | 104,881 | $86,002 | 0.02% |
| PROFUND ADVISORS LLC | 418,749 | $343,374 | 0.02% |
| Arlington Capital Management, Inc. | 27,735 | $22,743 | 0.02% |
| Hennion & Walsh Asset Management, Inc. | 382,158 | $313 | 0.02% |
| Rafferty Asset Management, LLC | 2,647,927 | $2,171,300 | 0.02% |
| Brainard Capital Management LLC | 16,666 | $13,666 | 0.01% |
| Beck Bode, LLC | 41,218 | $33,799 | 0.01% |